Entering text into the input field will update the search result below

Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial

  • Innovation Pharmaceuticals (OTCQB:IPIX -1.3%) announces that enrollment in the company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent.
  • The company said that it anticipates full enrollment to be completed in about two weeks.
  • Innovation is developing

Recommended For You

About IPIX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IPIX--
Innovation Pharmaceuticals Inc.